BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khatoon E, Parama D, Kumar A, Alqahtani MS, Abbas M, Girisa S, Sethi G, Kunnumakkara AB. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. Life Sci 2022;:120827. [PMID: 35907493 DOI: 10.1016/j.lfs.2022.120827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Makandar AI, Jain M, Yuba E, Sethi G, Gupta RK. Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy. Vaccines 2022;10:2049. [DOI: 10.3390/vaccines10122049] [Reference Citation Analysis]
2 Pang K, Shi Z, Wei L, Dong Y, Ma Y, Wang W, Wang G, Cao M, Dong J, Chen Y, Zhang P, Hao L, Xu H, Pan D, Chen Z, Han C. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resistance Updates 2022. [DOI: 10.1016/j.drup.2022.100907] [Reference Citation Analysis]
3 Kaur SD, Chellappan DK, Aljabali AA, Tambuwala M, Dua K, Kapoor DN. Recent advances in cancer therapy using PARP inhibitors. Med Oncol 2022;39:241. [PMID: 36180646 DOI: 10.1007/s12032-022-01840-7] [Reference Citation Analysis]
4 Lei Y, Zhang E, Bai L, Li Y. Autophagy in Cancer Immunotherapy. Cells 2022;11:2996. [DOI: 10.3390/cells11192996] [Reference Citation Analysis]